# Biofrontera Inc.: overview

BFRI · Nasdaq · CIK 1858685 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bfri.md) · [Financials](/companies/bfri/financials.md) · [Filings](/companies/bfri/filings.md) · [Insiders](/companies/bfri/insiders.md)

Latest reported revenue: [$12.0m](/filings/0001493152-26-037834.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-037834).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [9.0](/filings/0001493152-25-021945.md) | [12.6 d](/filings/0001493152-26-011625.md) | [8.6](/filings/0001493152-26-023119.md) | [9.0](/filings/0001493152-26-037834.md) | [7.0](/filings/0001493152-25-021945.md) | [17.1 d](/filings/0001493152-26-011625.md) | [10.1](/filings/0001493152-26-023119.md) | [12.0](/filings/0001493152-26-037834.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(55.0%)](/filings/0001493152-25-021945.md) | [(13.6%) d](/filings/0001493152-26-011625.md) | [(52.9%)](/filings/0001493152-26-023119.md) | [(56.2%)](/filings/0001493152-26-037834.md) | [(89.8%)](/filings/0001493152-25-021945.md) | [26.7% d](/filings/0001493152-26-011625.md) | [(42.8%)](/filings/0001493152-26-023119.md) | [(4.4%)](/filings/0001493152-26-037834.md) |
| Net margin | % | [(62.9%)](/filings/0001493152-25-021945.md) | [(11.1%) d](/filings/0001493152-26-011625.md) | [(48.9%)](/filings/0001493152-26-023119.md) | [(59.0%)](/filings/0001493152-26-037834.md) | [(95.1%)](/filings/0001493152-25-021945.md) | [33.0% d](/filings/0001493152-26-011625.md) | [(47.1%)](/filings/0001493152-26-023119.md) | [(5.0%)](/filings/0001493152-26-037834.md) |
| Diluted EPS | $ per share | [(0.98)](/filings/0001493152-25-021945.md) | not reported | [(0.47)](/filings/0001493152-26-023119.md) | [(0.57)](/filings/0001493152-26-037834.md) | [(0.62)](/filings/0001493152-25-021945.md) | not reported | [(0.41)](/filings/0001493152-26-023119.md) | [(0.05)](/filings/0001493152-26-037834.md) |
| Free cash flow | $m | [(1.2) d](/filings/0001493152-25-021945.md) | [(1.0) d](/filings/0001493152-26-011625.md) | [(4.1)](/filings/0001493152-26-023119.md) | [(3.0) d](/filings/0001493152-26-037834.md) | [(3.8) d](/filings/0001493152-25-021945.md) | [(2.4) d](/filings/0001493152-26-011625.md) | [(0.1)](/filings/0001493152-26-023119.md) | [(1.7) d](/filings/0001493152-26-037834.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [24.1](/filings/0001493152-23-007472.md) | [28.7](/filings/0001493152-24-010133.md) | [34.1](/filings/0001493152-25-011052.md) | [37.3](/filings/0001493152-26-011625.md) | [41.7](/filings/0001493152-26-011625.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(104.6%)](/filings/0001493152-23-007472.md) | [(64.8%)](/filings/0001493152-24-010133.md) | [(66.6%)](/filings/0001493152-25-011052.md) | [(46.1%)](/filings/0001493152-26-011625.md) | [(27.2%)](/filings/0001493152-26-011625.md) |
| Net margin | % | [(156.5%)](/filings/0001493152-23-007472.md) | [(2.2%)](/filings/0001493152-24-010133.md) | [(59.1%)](/filings/0001493152-25-011052.md) | [(47.6%)](/filings/0001493152-26-011625.md) | [(25.3%)](/filings/0001493152-26-011625.md) |
| Diluted EPS | $ per share | [(4.28)](/filings/0001493152-22-009519.md) | [(0.61)](/filings/0001493152-24-010133.md) | [(13.02)](/filings/0001493152-25-011052.md) | [(3.22)](/filings/0001493152-26-011625.md) | [(1.04)](/filings/0001493152-26-011625.md) |
| Free cash flow | $m | not reported | [(16.2)](/filings/0001493152-24-010133.md) | [(24.9)](/filings/0001493152-25-011052.md) | [(10.3)](/filings/0001493152-26-011625.md) | [(13.4)](/filings/0001493152-26-011625.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bfri/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Rosalind Advisors, Inc.](/funds/1622627.md) | 2026-06-30 | $1.2m | 1,275,609 |  | Added +111,647 |
| [AIGH Capital Management LLC](/funds/1835943.md) | 2026-06-30 | $699.6k | 739,910 |  | Reduced −175,300 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $148.9k | 157,505 |  | New +157,505 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $99.2k | 104,941 |  | New +104,941 |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $87.9k | 93,000 |  | New +93,000 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $72.5k | 76,689 |  | Reduced −32,611 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $67.5k | 71,380 |  | Added +19,126 |
| [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $58.4k | 61,697 |  | Unchanged |
| [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $49.1k | 51,894 |  | Added +29,401 |
| [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $29.8k | 31,536 |  | New +31,536 |

## Recent filings

[All 364 filings](/companies/bfri/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-14 | 09:29 ET | [8-K](/filings/0001493152-26-042508.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-042508 |
| 2026-08-13 | 16:41 ET | [10-Q](/filings/0001493152-26-037834.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037834 |
| 2026-08-13 | 09:00 ET | [8-K](/filings/0001493152-26-037610.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-037610 |
| 2026-07-22 | 16:40 ET | [10-K/A](/filings/0001493152-26-034251.md) | Annual report, amended, period 2025-12-31 | 0001493152-26-034251 |
| 2026-06-17 | 16:05 ET | [8-K](/filings/0001493152-26-029079.md) | 5.07 Shareholder vote results | 0001493152-26-029079 |
| 2026-05-14 | 16:28 ET | [10-Q](/filings/0001493152-26-023119.md) | Quarterly report, period 2026-03-31 | 0001493152-26-023119 |
| 2026-05-14 | 08:00 ET | [8-K](/filings/0001493152-26-022875.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-022875 |
| 2026-04-30 | 16:40 ET | [DEF 14A](/filings/0001493152-26-020616.md) | Proxy statement, period 2026-04-30 | 0001493152-26-020616 |
| 2026-03-19 | 16:15 ET | [10-K](/filings/0001493152-26-011625.md) | Annual report, period 2025-12-31 | 0001493152-26-011625 |
| 2026-03-19 | 09:35 ET | [8-K](/filings/0001493152-26-011545.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-011545 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-011625.md), filed Mar 19, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/7857de0a-82eb-4352-bb64-fba241d3ed3b)

## About the filer

- CIK: 1858685
- Tickers: BFRI, BFRIW
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.